Fiche publication
Date publication
avril 2000
Journal
Anti-cancer drugs
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MERLIN Jean-Louis
Tous les auteurs :
Merlin JL, Bour-Dill C, Marchal S, Bastien L, Gramain MP
Lien Pubmed
Résumé
DNA fragmentation was investigated in MCF7 and the MCF7TAX19 paclitaxel-resistant subline exposed to paclitaxel for 24 h. No nucleosome-sized DNA fragmentation was observed by DNA agarose gel electrophoresis in both cell lines. However, DNA fragmentation was detected by flow cytometry sub-G1 peak analysis in both cell lines immediately after paclitaxel exposure. Nuclear abnormalities were observed in both cell lines in the range of 35-40% of the total cell population. This value was reached immediately in MCF7 cells but was time-delayed in MCF7TAX19 cells. Significant morphologic differences were observed between sensitive and resistant cell lines, 24 h after exposure to 50 nmol/l paclitaxel. Although no difference in the sub-G1 cell population was observed between sensitive and resistant cells, a significantly higher rate of multinucleated cell features was observed in resistant cells.
Mots clés
Adenocarcinoma, drug therapy, Antineoplastic Agents, Phytogenic, pharmacology, Breast Neoplasms, drug therapy, Cell Cycle, drug effects, Cell Survival, drug effects, DNA Fragmentation, drug effects, DNA, Neoplasm, drug effects, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Electrophoresis, Agar Gel, Female, Humans, Microscopy, Fluorescence, Paclitaxel, pharmacology, Time Factors, Tumor Cells, Cultured, drug effects
Référence
Anticancer Drugs. 2000 Apr;11(4):295-302
